Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Nobel for mRNA: Which other biotech stocks might be overlooked?
08:33am, Friday, 06'th Oct 2023
Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA v
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
08:27am, Friday, 06'th Oct 2023
With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows, a
(MRK) Rises As Market Takes a Dip: Key Facts
07:32pm, Thursday, 05'th Oct 2023
In the most recent trading session, Merck (MRK) closed at $103.60, indicating a +1.4% shift from the previous trading day.
Merck blockbuster shows promise in bladder cancer
08:43am, Thursday, 05'th Oct 2023
Merck & Co Inc (NYSE:MRK) has announced promising results from its phase III clinical trial of its blockbuster cancer drug Keytruda in people with certain types of bladder cancer. The study met one of
Merck reports positive results in late-stage trial of Keytruda as treatment for bladder cancer
07:26am, Thursday, 05'th Oct 2023
Merck & Co. Inc. MRK, +0.39% said Thursday a late-stage trial of its cancer treatment Keytruda met its main goal of disease-free survival for patients with advanced bladder cancer. The Rahway, N.J.
Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26
06:45am, Thursday, 05'th Oct 2023
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26.
US plans shift of Merck COVID treatment to commercial market
12:35pm, Wednesday, 04'th Oct 2023
The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.
Drugmakers opt in to Medicare drug price negotiations – here's what happens next
03:34pm, Monday, 02'nd Oct 2023
The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.
FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease
12:46pm, Monday, 02'nd Oct 2023
The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.
As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment
10:20am, Friday, 29'th Sep 2023
Several major drugmakers, including Merck & Co. Inc. MRK and AstraZeneca PLC AZN, say they're moving forward with the Medicare drug-price negotiation process ahead of this Sunday's deadline to sign ag
Bionomics shares soar almost 400% after positive phase IIb results from PTSD treatment
10:00am, Thursday, 28'th Sep 2023
Shares of Bionomics Limited rocketed 387% after phase IIb trial results showed its lead asset had the potential to become a best-in-class treatment for post-traumatic stress disorder (PTSD). Researche
Merck's COVID antiviral may be linked to virus mutations, study finds
02:39pm, Monday, 25'th Sep 2023
An antiviral drug that was granted an emergency use authorization by the U.S. Food and Drug Administration in December 2021 may be linked to mutations in the virus, according to a new study released o
Merck Covid drug linked to virus mutations that can spread between people, new study says
02:13pm, Monday, 25'th Sep 2023
There is still no evidence that molnupiravir, sold under the brand name Lagevrio, has produced more transmissible or severe variants of Covid.
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
01:32pm, Monday, 25'th Sep 2023
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump
12:40pm, Friday, 22'nd Sep 2023
Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in combina
